Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Completed Phase 1 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0029503 (Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00023959Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerTreatment